New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - prochlorperazine maleate 25mg - suppository - 25 mg - active: prochlorperazine maleate 25mg excipient: suppository base e75 suppository base w35 - prochlorperazine is used for nausea and vomiting from whatever cause. it may also be used for migraine, schizophrenia (particularly in the chronic stage) and acute mania.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - prochlorperazine mesilate 25mg - suppository - 25 mg - active: prochlorperazine mesilate 25mg

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - prochlorperazine mesilate 5mg - suppository - 5 mg - active: prochlorperazine mesilate 5mg

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - prochlorperazine maleate 5mg - suppository - 5 mg - active: prochlorperazine maleate 5mg excipient: suppository base e75 suppository base w35

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - prochlorperazine maleate - suppository - 25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - prochlorperazine maleate - suppository - 5mg

Namibia - English - Namibia Medicines Regulatory Council

aventis pharma (pty) ltd - prochlorperazine maleate - suppository - prochlorperazine base equivalent to prochlorperazine maleate suppositories 5 mg.

Namibia - English - Namibia Medicines Regulatory Council

aventis pharma (pty) ltd - prochloperazine maleate - suppository - each suppository contains prochloperazine maleate 25 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - isosorbide dinitrate, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; erythrosine; magnesium stearate - this product accepted for registration as 'currently supplied' at the time of commencement of the act. conditions varied as approved in theletter of 3 april 1992 from dr bijoy varma. indicated for angina pectoris and management of congestive heart failure. indications as at 23 may 2005 : treatment of angina pectoris (classic effort associated angina, chronic stable angina, vaso-spastic angina, variant angina, unstable angina and angina decubitus) and myocardial ischaemia due to ischaemic heart disease, and an aid in the management of left ventricular failure, either alone or as part of the syndrome of congestive heart failure. sublingual - prevention and treatment of angina pectoris and myocardial ischaemia due to ischaemic heart disease. acute and chronic left ventricular failure, either alone or as part of the syndrome of congestive heart failure to improve cardiac performance and stabilise the patient's condition.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - prochlorperazine maleate -